SCHEMBL3885757

SCHEMBL3885757

Cc1cnc(C(=O)N2CCC(c3nc4c(s3)CCN(C3=CC=C3)CC4)CC2)cn1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 7/20 0.37
ALDH1A1 P00352 4/20 0.36
UBE2M P61081 3/20 0.35
DCUN1D1 Q96GG9 3/20 0.35
LMNA P02545 2/20 0.33
POLB P06746 2/20 0.33
ATM Q13315 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
NAMPT P43490 1/20 0.32
TRPC6 Q9Y210 1/20 0.32
MYC P01106 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3881507 0.88 GRM5 (0.35) GRM5ALDH1A1UBE2MDCUN1D1LMNA
SCHEMBL3880379 0.87 UBE2M (0.41) GRM5ALDH1A1UBE2MDCUN1D1LMNA
SCHEMBL3877923 0.86 GRM5 (0.44) GRM5ALDH1A1UBE2MDCUN1D1LMNA
SCHEMBL3878394 0.86 UBE2M (0.36) GRM5ALDH1A1UBE2MDCUN1D1LMNA
SCHEMBL3879404 0.86 UBE2M (0.39) GRM5ALDH1A1UBE2MDCUN1D1LMNA
SCHEMBL3878904 0.85 UBE2M (0.36) GRM5ALDH1A1UBE2MDCUN1D1LMNA
SCHEMBL3878476 0.84 RBP4 (0.43) GRM5UBE2MDCUN1D1MAPT
SCHEMBL3878678 0.84 GRM5 (0.43) GRM5ALDH1A1UBE2MDCUN1D1MAPT
SCHEMBL3879018 0.84 UBE2M (0.42) ALDH1A1UBE2MDCUN1D1LMNAMEN1
SCHEMBL3888351 0.84 SLC9A1 (0.42) GRM5ALDH1A1UBE2MDCUN1D1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP claimed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US claimed
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed
EP-1858900-A1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006097691-A1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor HRH3, HRH4, HRH2 GRM5 26/4885ALDH1A1 1866/4885UBE2M 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.